Search Result

Results for "

CB2 receptor agonists

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Bacterial (1) Cannabinoid Receptor (66) Caspase (1) Cholinesterase (ChE) (1) Drug Metabolite (1) Endogenous Metabolite (11) FAAH (1) GlyT (2) GPR55 (2) HIF/HIF Prolyl-Hydroxylase (1) Isotope-Labeled Compounds (3) PDK-1 (1) Potassium Channel (1) PPAR (1) Virus Protease (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Infection (5) Inflammation/Immunology (21) Metabolic Disease (6) Neurological Disease (45)
Click Chemistry:	Azide (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113591

CB2 receptor agonist 10	Cannabinoid Receptor	Others
CB2 receptor agonist 10 is a *CB2* receptor agonist with a K_i of 3.7 nM for hCB2, a K_i of 110 nM for hCB1, and an EC₅₀ of 0.52 nM for hCB2 .

HY-110036A

GW405833 hydrochloride L768242 hydrochloride	Cannabinoid Receptor	Neurological Disease
GW-405833 (L768242) hydrochloride is a potent, selective cannabinoid receptor 2 (CB₂) agonist with an EC₅₀ of 50.7 nM. GW-405833 hydrochloride also behaves as a noncompetitive CB₁ antagonist. GW-405833 hydrochloride suppresses inflammatory and neuropathic pain .

HY-132217

CB2 receptor agonist 2	Cannabinoid Receptor	Neurological Disease
CB2 receptor agonist 2 is a potent and selective agonist for the *CB2* (cannabinoid type 2) receptor with a K_i of 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for *CB2* .

HY-107471

CB2 receptor agonist 3 GP2a	Cannabinoid Receptor	Cancer
CB2 receptor agonist 3 is a robust and selective *CB2* cannabinoid agonist with K_is of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells .

HY-12761

A-836339	Cannabinoid Receptor	Neurological Disease
A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.

HY-14167

GW842166X	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GW842166X is a potent and selective *cannabinoid receptor* 2** (CB2) agonist with IC₅₀ values of 63 and 91 nM for human and rat CB2, respectively.

HY-163394

CB2 receptor agonist 6	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
CB2 receptor agonist 6 (compound 70) is an agonist of *CB2R, with EC₅₀* of 162 nM. The IC₅₀ values of CB2 receptor agonist 6 are 4.83 μM for CB1R and 0.88 μM for *CB2R. CB2* receptor agonist 6 is a neuroprotective agent that can be used for the reseach of neurological disease .

HY-14160

CB2 receptor agonist 7	Cannabinoid Receptor	Neurological Disease Cancer
CB2 receptor agonist 7 (Compound 5B) is a cannabinoid 2 (CB2) receptor agonist with blood-brain barrier permeability .

HY-173083

MDA7	Cannabinoid Receptor	Neurological Disease
MDA7 is the selective agonist for *cannabinoid receptor* 2 with EC₅₀** of 128 nM and 67.4 nM in human CB2 receptor and rat CB2 receptor. MDA7 exhibits good affinity to human CB2 receptor and rat CB2 receptor with K_i of 422 nM and 238 nM. MDA7 exhibits analgesic activity in rats models .

HY-168338

CB2 receptor agonist 8	Cannabinoid Receptor Caspase	Cancer
CB2 receptor agonist 8 (Compound 17) is an agonist for *cannabinoid receptor* 2 (CB2 receptor*). CB2* receptor agonist 8 exhibits cytotoxicity in cells U87, RPMI 8226, HL-60, and L929 with IC₅₀s of 91.03, 16.29, 23.51 and 564.6 μM, respectively. CB2 receptor agonist 8 activates caspase 3/7, increases the expressions of pro-apoptotic genes BAX, BAD, BIM and tumor suppressor genes p53, and induces apoptosis in U87. CB2 receptor agonist 8 inhibits the migration of U87 .

HY-N1415

β-Caryophyllene 1 Publications Verification (-)-(E)-Caryophyllene; (−)-β-caryophyllene; (−)-trans-Caryophyllene	Cannabinoid Receptor Endogenous Metabolite	Infection Neurological Disease Cancer
β-Caryophyllene is a **CB2 receptor** agonist.

HY-168734

CB2 receptor agonist 9	Cannabinoid Receptor	Inflammation/Immunology
CB2 receptor agonist 9 (Compound 33) is an orally active agonist for *cannabinoid receptor* 2 (CB2 receptor) with an EC₅₀** of 16.2 nM. CB2 receptor agonist 9 inhibits the expression of TNF-α, IL-1β and IL-6, exhibits anti-inflammatory efficacy in DDS (HY-116282)-induced mouse acute colitis model .

HY-155481

CB2 receptor antagonist 3	Cannabinoid Receptor	Neurological Disease
CB2 receptor antagonist 3 (compound (S)-1) is an inverse agonist of the cannabinoid receptor CB2R with Kd=39 nM. CB2 receptor antagonist 3 can be used as a tool to synthesize a variety of CB2R probes .

HY-100328

CB2R-IN-1	Cannabinoid Receptor	Neurological Disease
CB2R-IN-1 is a potent cannabinoid CB₂ receptor inverse agonist with a K_i of 0.9 nM.

HY-110040

L759633	Cannabinoid Receptor	Metabolic Disease Inflammation/Immunology
L759633 is a potent and selective agonist of cannabinoid receptor (CB₂) receptor, with K_is of 6.4 nM and 1043 nM for CB2 and CB1 receptors, respectively. L759633 can inhibit Forskolin-stimulated cAMP production .

HY-128040

Virodhamine hydrochloride	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine (hydrochloride) is a cannabinoid CB1 receptor partial agonist and cannabinoid *CB2* receptor full agonist .

HY-100488

Bay 59-3074	Cannabinoid Receptor	Cancer
Bay 59-3074 is a selective cannabinoid **CB₁/CB₂ receptor** partial agonist with K_i values of 48.3 and 45.5 nM at human CB₁ and *CB₂* receptors, respectively. Bay 59-3074 has analgesic properties .

HY-119744

BAY 38-7271	Cannabinoid Receptor	Neurological Disease
BAY 38-7271 is selective and highly potent and cannabinoid **CB₁/CB₂ receptor** agonist, with K_is of 1.85 nM and 5.96 nM for recombinant human CB₁ receptor and CB₂ receptor, respectively. BAY 38-7271 has strong neuroprotective properties .

HY-155481A

CB2 receptor antagonist 4	Cannabinoid Receptor	Others
CB2 receptor antagonist 4 (compound (R)-1) is a *CB2R*-selective inverse agonist with a K_d value of 39 nM .

HY-110048

O-2545 hydrochloride	Cannabinoid Receptor	Neurological Disease
O-2545 hydrochloride is a highly potent, water-soluble *CB1/CB2* receptor agonist (with K_i values of 1.5 and 0.32 nM for CB1 and *CB2* respectively), can be used for epilepsy, pain, multiple sclerosis research .

HY-W751734

HU 433	Cannabinoid Receptor	Others Neurological Disease Inflammation/Immunology
HU 433 is a synthetic cannabinoid *CB2* receptor agonist and is the enantiomer of HU 308 (HY-161510). HU 433 exerts its anti-inflammatory and neuroprotective effects by binding to *CB2* receptors. HU 433 can be used in the study of neuroinflammation and retinal diseases .

HY-117403

AB-FUBICA	Cannabinoid Receptor Potassium Channel
AB-FUBICA (Compound 13) is a CB1 and *CB2* receptor agonist that activates G-protein coupled inwardly rectifying potassium channels (GIRK) by binding to CB1 and *CB2* receptors, displaying notable cannabinoid-like activity. AB-FUBICA has EC₅₀ values of 21 nM for CB1 and 15 nM for *CB2*. AB-FUBICA may be suitable for studying pain management, neurodegenerative diseases, and inflammation-related mechanisms .

HY-124283A

LEI-101	Cannabinoid Receptor	Neurological Disease
LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC₅₀ of 8 for hCB2, and a pK_i of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors .

HY-14900

Tedalinab GRC-10693	Cannabinoid Receptor	Inflammation/Immunology
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 *(CB2)* agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment .

HY-103331

COR170	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
COR170 (11u) is a selective *CB2* inverse-agonist which is a 4-quinolone-3-carboxylic acid derivative with a K_i value of 3.8 nM for CB2 receptor. COR170 can be used for the research of inflammation and neuroprotection .

HY-124283

LEI-101 free base	Endogenous Metabolite	Inflammation/Immunology
LEI-101 free base is a selective and orally bioavailable CB2 receptor agonist with the potential to inhibit diseases associated with inflammation and/or oxidative stress. LEI-101 free base has a binding potency to CB2 receptors that is approximately 100 times higher than that to CB1 receptors. Its pEC50 value on CB2 receptors is 8, while its pKi value on hERG is less than 4. LEI-101 may have an inhibitory effect on conditions such as kidney disease .

HY-108067

SAD448	Cannabinoid Receptor	Others
SAD448 is a CB1 and **CB2 receptor** agonist. SAD448 can lower intraocular pressure (IOP) .

HY-134615

Mead ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Mead ethanolamide is an endogenous cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against CB1 and *CB2*, respectively .

HY-103325

JTE-907	Cannabinoid Receptor	Inflammation/Immunology
JTE-907 is a highly selective, orally active **CB2 receptor** inverse agonist and exerts anti-inflammatory effects in vivo .

HY-N1415S

β-Caryophyllene-d2	Cannabinoid Receptor Endogenous Metabolite	Infection Neurological Disease Cancer
β-Caryophyllene-d₂ is deuterium labeled β-Caryophyllene. β-Caryophyllene is a CB2 receptor agonist.

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a *cannabinoid (CB) receptor* agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and **CB2 receptors, respectively .

HY-110047

CB65	Cannabinoid Receptor	Inflammation/Immunology
CB65 is a potent and high affinity *CB2* selective agonist with a K_i value of 3.3 nM. CB65 exhibits a K_i of >1000 nM for CB1 receptor .

HY-111110

Olorinab 1 Publications Verification APD 371	Cannabinoid Receptor	Neurological Disease
Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 *(CB₂)* agonist, with an EC₅₀ of 6.2 nM for hCB₂.

HY-101765

GW 833972A	Cannabinoid Receptor	Neurological Disease
GW 833972A is a selective **CB2 receptor** agonist. GW 833972A inhibits induced nerve depolarization and citric acid-induced cough in animal models .

HY-119352

S-2 Methanandamide	Cannabinoid Receptor	Neurological Disease
S-2 Methanandamide is a potent CB1 receptor agonist, with IC₅₀ values of 173 nM (with PMSF) and 8216 nM for CB1 and CB2, respectively .

HY-N1415R

β-Caryophyllene (Standard) 1 Publications Verification (-)-(E)-Caryophyllene(Standard); (−)-β-caryophyllene(Standard); (−)-trans-Caryophyllene (Standard)	Cannabinoid Receptor Endogenous Metabolite	Infection Neurological Disease Cancer
β-Caryophyllene (Standard) is the analytical standard of β-Caryophyllene. This product is intended for research and analytical applications. β-Caryophyllene is a **CB2 receptor** agonist.

HY-145153

S-777469	Cannabinoid Receptor	Neurological Disease
S-777469 is a selective and orally available cannabinoid type 2 receptor *(CB2)* agonist with a K_i of 36 nM. S-777469 significantly suppresses compound 48/80-induced scratching behavior in mice in a dose-dependent manner. S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism .

HY-B1290S3

2-Phenylethanol-13C2 Phenylethyl alcohol-¹³C₂; Phenethyl alcohol-¹³C₂; Benzyl carbinol-¹³C₂	Bacterial Virus Protease Isotope-Labeled Compounds	Infection
2-Phenylethanol- ¹³C₂ is ¹³C labeled β-Caryophyllene (HY-B1290). β-Caryophyllene is a **CB2 receptor** agonist.

HY-119104

AZD1940	Cannabinoid Receptor	Neurological Disease
AZD1940 is an orally active, high affinity cannabinoid CB1/CB2 receptor agonist with pK_i values of 7.93 and 9.06 for human CB1R and *CB2R*, respectively. AZD1940 shows a robust analgesia action .

HY-100778

SMM-189	Cannabinoid Receptor	Neurological Disease
SMM-189 is a potent and selective cannabinoid receptor 2 (CB2) inverse agonist. SMM-189 plays an important role in neurodegenerative disorders and traumatic brain injury research .

HY-110050

GP1a	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization .

HY-110065

SER-601	Cannabinoid Receptor	Neurological Disease
SER-601 is a potent and selective peripheral cannabinoid (CB2) receptor agonist with a K_i of 6.3 nM. SER-601 has analgesic and antidiabetic properties and can be used for relevant research .

HY-135280

MRL-650 CB1 inverse agonist 1	Cannabinoid Receptor	Metabolic Disease
MRL-650 (CB1 inverse agonist 1) is a highly potent, orally active, and specific inverse agonist of CB1 receptor with IC₅₀s of 7.5 nM and 4100 nM for CB1 and **CB2 receptors**, respectively. Anorexigenic effects .

HY-163825

RNB-61	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
RNB-61 is an oral active agonist of cannabinoid CB2 receptor (CB2R), with the K_i ranging from 0.13 nM to 1.81 nM. RNB-61 has nephroprotective and/or antifibrotic effects. RNB-61 has negligible penetration into the brain .

HY-150029

CB1/2 agonist 3	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a *CB1/CB2* (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively .

HY-15451

MDA 19 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a K_i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .

HY-116418

Virodhamine	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of *CB2* receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-145604

Vicasinabin RG7774	Cannabinoid Receptor	Neurological Disease
Vicasinabin (RG7774) is the potent agonist of *cannabinoid receptor* 2** (CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1) .

HY-110036

GW-405833 L768242	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GW-405833 (L768242) is a potent, selective cannabinoid receptor 2 (CB₂) agonist with an EC₅₀ of 50.7 nM. GW-405833 also behaves as a noncompetitive CB₁ antagonist. GW-405833 suppresses inflammatory and neuropathic pain .

HY-110194

Virodhamine TFA	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine TFA is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of *CB2* receptor. Virodhamine TFA induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine TFA can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

Cat. No.	Product Name	Target	Research Area

HY-P1397A

RVD-Hpα TFA	Cannabinoid Receptor	Cardiovascular Disease
RVD-Hpα TFA is the N-terminally extended form of human hemopressin that acts as a selective CB1 receptor agonist. RVD-Hpα TFA increases intracellular Ca ²⁺ levels in cells expressing CB1 receptors in vitro. RVD-Hpα TFA also high affinity CB2 positive allosteric modulator (K_i=50 nM).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1415

β-Caryophyllene 1 Publications Verification (-)-(E)-Caryophyllene; (−)-β-caryophyllene; (−)-trans-Caryophyllene	Structural Classification Neurological Disease Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Infection other families Terpenoids Sesquiterpenes Disease Research Fields Cancer	Cannabinoid Receptor Endogenous Metabolite
β-Caryophyllene is a **CB2 receptor** agonist.

HY-N1415R

β-Caryophyllene (Standard) 1 Publications Verification (-)-(E)-Caryophyllene(Standard); (−)-β-caryophyllene(Standard); (−)-trans-Caryophyllene (Standard)	Infection Structural Classification other families Neurological Disease Classification of Application Fields Anti-aging Terpenoids Source classification Plants Endogenous metabolite Disease Research Fields Cancer	Cannabinoid Receptor Endogenous Metabolite
β-Caryophyllene (Standard) is the analytical standard of β-Caryophyllene. This product is intended for research and analytical applications. β-Caryophyllene is a **CB2 receptor** agonist.

HY-116418

Virodhamine	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Cannabinoid Receptor
Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of *CB2* receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-116637

Tetrahydromagnolol Magnolignan	Structural Classification Classification of Application Fields Magnoliaceae Source classification Phenols Polyphenols Magnolia Liliflora Desr. Plants Inflammation/Immunology Disease Research Fields	Cannabinoid Receptor GPR55 Drug Metabolite
Tetrahydromagnolol (Magnolignan), the main metabolite of Magnolol, is a potent and selective cannabinoidCB2 receptor agonist (EC₅₀ =170 nM) and GPR55 antagonist. The K_i of Tetrahydromagnolol for *CB2* is 416 nM, 20-fold higher than for the CB1 receptor. Magnolol shows antifungal, anti-inflammatory and analgesic effects .

HY-103332

N-Arachidonylglycine 1 Publications Verification NA-Gly	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	GlyT Endogenous Metabolite
N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

HY-134615

Mead ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Cannabinoid Receptor Endogenous Metabolite
Mead ethanolamide is an endogenous cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against CB1 and *CB2*, respectively .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Cannabinoid Receptor Endogenous Metabolite
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a *cannabinoid (CB) receptor* agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and **CB2 receptors, respectively .

Cat. No.	Product Name	Chemical Structure

HY-124089S

Eicosapentaenoyl ethanolamide-d4

Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant[1][2].

HY-103332S

N-Arachidonylglycine-d8

N-Arachidonylglycine-d8 is a deuterated labeled N-Arachidonylglycine . N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .